Questions Answered in This Report:

    • What are the treatment drivers and goals for moderate to severe ulcerative colitis? 
    • What attributes are key influences, which have limited impact, and which are hidden opportunities? 
    • How do current therapies perform on key treatment drivers and goals for moderate to severe ulcerative colitis? 
    • What are the prevailing areas of unmet need and opportunity in moderate to severe ulcerative colitis? 
    • What trade-offs across different clinical attributes and price are acceptable to and European gastroenterologists for a hypothetical new moderate to severe ulcerative colitis drug? 


     

Scope:

Current therapies, or combinations thereof, used to treat moderate to severe ulcerative colitis are moderately effective in managing patient symptoms. However, efficacy limitations and/or safety risks with long-term use still exist. Therefore, a substantial level of unmet need remains in the treatment of ulcerative colitis, and addressing this need could result in substantial commercial opportunity. 
Unmet Need provides quantitative insight into and European physicians’ perceptions of key treatment drivers and goals and the current level of unmet need associated with the treatment of moderate to severe ulcerative colitis. We analyze the commercial opportunities and how emerging therapies can capitalize on these opportunities. 
 
Markets covered: United States, France, Germany, United Kingdom 
Primary research: Survey of 61 and 31 European gastroenterologists fielded in December 2016 
Key companies: AbbVie, Biogen, Celgene, Celltrion, Janssen, Merck, Pfizer, Roche, Shire, Takeda 
Key drugs: Azathioprine, Entyvio, etrolizumab, Flixabi, Humira, Inflectra, Lialda/Mezavant/Mesavant XL , ozanimod, Remicade, Remsima, Simponi, Xeljanz 


Related Reports

Ulcerative Colitis | Current Treatment | Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US) - Pediatric

MARKET OUTLOOK Conventional therapies (5-ASAs, corticosteroids) are typically used to treat mild to moderate pediatric ulcerative co...

View Details

Ulcerative Colitis | Landscape & Forecast | Disease Landscape & Forecast

The ulcerative colitis (UC) market is expected to grow steadily over the next decade. The entry of first-in-UC oral...

View Details

Ulcerative Colitis | Epidemiology | Extrapolated Worldwide Coverage

DRG’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key ulcerative colitis pat...

View Details

Ulcerative Colitis | Current Treatment | Detailed, Expanded Analysis (EU5)

Multiple well-established therapies are currently available to treat ulcerative colitis (UC) in Europe. TNF-&alp...

View Details